Drug Profile
Interferon beta-1b biosimilar - Harvest Moon Pharmaceuticals
Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Harvest Moon Pharmaceuticals
- Class Antineoplastics; Antivirals; Interferons; Recombinant proteins
- Mechanism of Action Interferon beta stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Multiple-sclerosis in European Union (SC, Injection)
- 22 Aug 2013 Clinical trials in Multiple sclerosis in European Union (SC)